Trade Phathom Pharmaceuticals, Inc. - PHAT CFD

Trading Conditions

• Spread: 0.06
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 9.07
• Open: 8.92
• 1-Year Change: -12.12%
• Day's Range: 8.92 - 9.26

Phathom Pharmaceuticals, Inc. Company profile

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company, which is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan is effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases and impact millions of people. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. Approximately 30% of GERD patients have erosive esophagitis. H. pylori is a bacterial pathogen.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Phathom Pharmaceuticals Inc revenues was not reported. Net loss increased 11% to $143.9M. Higher net loss reflects General and administrative - Balancing increase from $23.1M to $49.8M (expense), Stock-based Compensation in SGA increase from $4.4M to $13M (expense), Stock-based Compensation in R&D increase from $1.5M to $3.8M (expense).